Law Firms Prepare For Celebrex Cases After Pfizer Says 1999 Trial Revealed Cardiovascular Risks, Says Weitz & Luxenberg, PC

Main Category: Arthritis / Rheumatology
Article Date: 10 Feb 2005 - 9:00 PDT

email to a friend   printer friendly   opinions  

Manhattan personal injury firm Weitz & Luxenberg has launched an aggressive marketing campaign seeking patients injured by the arthritis and pain medication Celebrex after the drug's manufacturer acknowledged that a 1999 clinical trial showed clear cardiovascular risks in elderly patients taking the drug.

As late as October of 2004, in response to the Vioxx recall, Pfizer said that no studies had ever shown increased Celebrex-related cardiovascular risks. Now Pfizer has acknowledged that, in a 1999 study where Celebrex was tested as a treatment for Alzheimer's disease, patients taking Celebrex quadrupled their risk for a heart attack versus those taking a placebo. This study was not published until June of 2001, four months after the FDA conducted a safety review of Vioxx and Celebrex.

Personal injury law firms such as Weitz & Luxenberg are concentrating on the most serious Celebrex-related injuries; heart attacks, strokes, and death, paying particular attention to the dosage and frequency with which the drug was taken when evaluating potential lawsuits.

In the firm's most recent television advertisement, a Celebrex tablet falls into a glass of water, which immediately turns murky. An announcer says, "Don't let Pfizer muddy the legal waters around Celebrex. Suppressed clinical trials prove it's dangerous medicine."

In subsequent frames, tablets with the firm's name drop into the glass, and the water begins to clear. The announcer goes on to say, "Weitz & Luxenberg has already accepted cases and begun a landmark investigation." As the water becomes completely clear, the announcer concludes, "Be clear about your rights as a Celebrex user."

With marketing campaigns such as these, personal injury firms hope to attract Celebrex users who have suffered heart attacks, strokes, and other cardiovascular injuries. In anticipation of a heavy case load, Weitz & Luxenberg has assigned a team of lawyers with a track record of success and experience in drug litigation matters.

People who have been injured by Celebrex can contact Weitz & Luxenberg. Interested parties should call the Client Relations Department at 1 (800) 476-6070, email clientrelations@weitzlux.com, and view the firm's website at http://www.weitzlux.com.

Contact:

David Kufeld, Director of Marketing
Weitz & Luxenberg, PC
180 Maiden Lane, New York, NY 10038
(212) 558-5682 - phone
(212) 558-5692 - fax
dkufeld@weitzlux.com
http://www.weitzlux.com

Distributed by eReleases - http://www.ereleases.com
9403 Good Spring Dr. Suite P-3, Perry Hall, MD 21128

• Additional
• References
• Citations